methyl 10,11-dihydro-5H-dibenzo[b,f]azepine-4-carboxylate | 22965-12-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: methyl 10,11-dihydro-5H-dibenzo[b,f]azepine-4-carboxylate
• 英文别名: 4-Methoxycarbonyl-10,11-dihydro-5H-dibenzazepin；10,11-dihydro-5H-dibenzo[b,f]azepine-4-carboxylic acid methyl ester；methyl 6,11-dihydro-5H-benzo[b][1]benzazepine-1-carboxylate
• CAS: 22965-12-4
• 化学式: C₁₆H₁₅NO₂
• 分子量: 253.301
• InChiKey: KYPIWWNLKNXWIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] TREATMENT OF GENETIC DISEASES CHARACTERIZED BY UNSTABLE mRNAs<br/>[FR] TRAITEMENT DE MALADIES GÉNÉTIQUES CARACTÉRISÉES PAR DES ARNM INSTABLES
  申请人：YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD

  公开号：WO2021059270A2

  公开（公告）日：2021-04-01

  Methods of treating a disease characterized by mRNA instability or nonsense-mediated decay of an mRNA of a disease-associated gene in a subject by administering a pharmaceutical composition comprising at least one agent that decreases FTO expression, function or both are provided. Kits and pharmaceutical compositions comprising an agent that decreases FTO expression, function or both and a read-through promoting agent are also provided, as are methods of determining suitability of a subject to be treated with an agent that decreases FTO expression, function or both.